Genomic Analysis of Follicular Dendritic Cell Sarcoma by Molecular
Modern Pathology (2017) 30, 1321–1334 © 2017 USCAP, Inc All rights reserved 0893-3952/17 $32.00 1321 Genomic analysis of follicular dendritic cell sarcoma by molecular inversion probe array reveals tumor suppressor-driven biology Erica F Andersen1,2, Christian N Paxton2, Dennis P O’Malley3,4, Abner Louissaint Jr5, Jason L Hornick6, Gabriel K Griffin6, Yuri Fedoriw7, Young S Kim8, Lawrence M Weiss3, Sherrie L Perkins1,2 and Sarah T South1,2,9 1Department of Pathology, University of Utah, Salt Lake City, UT, USA; 2Institute for Clinical and Experimental Pathology, ARUP Laboratories, Salt Lake City, UT, USA; 3Department of Pathology, Clarient/ Neogenomics, Aliso Viejo, CA, USA; 4Department of Pathology, M.D. Anderson Cancer Center/University of Texas, Houston, TX, USA; 5Department of Pathology, Massachusetts General Hospital, Boston, MA, USA; 6Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA; 7Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA and 8Department of Pathology, City of Hope National Medical Center, Duarte, CA, USA Follicular dendritic cell sarcoma is a rare malignant neoplasm of dendritic cell origin that is currently poorly characterized by genetic studies. To investigate whether recurrent genomic alterations may underlie the biology of follicular dendritic cell sarcoma and to identify potential contributory regions and genes, molecular inversion probe array analysis was performed on 14 independent formalin-fixed, paraffin-embedded samples. Abnormal genomic profiles were observed in 11 out of 14 (79%) cases. The majority showed extensive genomic complexity that was predominantly represented by hemizygous losses affecting multiple chromosomes. Alterations of chromosomal regions 1p (55%), 2p (55%), 3p (82%), 3q (45%), 6q (55%), 7q (73%), 8p (45%), 9p (64%), 11q (64%), 13q (91%), 14q (82%), 15q (64%), 17p (55%), 18q (64%), and 22q (55%) were recurrent across the 11 samples showing abnormal genomic profiles.
[Show full text]